PMC:7784830 / 4713-5115
Annnotations
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
86 | 67-71 | Chemical | denotes | ODFs | |
87 | 162-167 | Chemical | denotes | lipid | MESH:D008055 |
88 | 229-235 | Chemical | denotes | silica | MESH:D012822 |
89 | 320-324 | Chemical | denotes | ODFs |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T45 | 0-402 | Sentence | denotes | Drugs are either directly introduced [25–28] in the formulation of ODFs or size reduced and converted to solid dispersions [29] or nanoparticles [30,31] or solid lipid microparticles [32] or micronized and surface modified using silica [33] which not only help in enhancing the amount of drug that could be loaded on to ODFs but also help in enhancing the release rate and, bioavailability of the drug. |